UOC
XENE icon

UBS O'Connor’s Xenon Pharmaceuticals XENE Stock Holding History

UBS O'Connor’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,987
Closed -$344K – 643
2024
Q1 		$344K Sell
7,987
-6,689
-46% -$308K 0.01% 362
2023
Q4 		$676K Sell
14,676
-34,000
-70% -$1.2M 0.02% 319
2023
Q3 		$1.66M Buy
48,676
+10,000
+26% +$374K 0.03% 266
2023
Q2 		$1.49M Sell
38,676
-24,715
-39% -$982K 0.03% 340
2023
Q1 		$2.27M Sell
63,391
-981
-2% -$36.2K 0.05% 295
2022
Q4 		$2.54M Buy
64,372
+10,164
+19% +$370K 0.05% 348
2022
Q3 		$1.96M Sell
54,208
-42,000
-44% -$1.51M 0.02% 629
2022
Q2 		$2.93M Buy
96,208
+53,706
+126% +$1.62M 0.03% 473
2022
Q1 		$1.3M Buy
+42,502
New +$1.27M 0.01% 658

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS O'Connor's XENE Position: Q2 2024 in Review

UBS O'Connor sold out of Xenon Pharmaceuticals (XENE) in Q2 2024, closing a stake of 7,987 shares — an estimated $344K sold.

UBS O'Connor first reported a position in XENE in Q1 2022 and held it in 9 quarters. The position peaked at $2.93M in Q2 2022. 213 funds tracked by Wall St. Rank hold XENE as of Q2 2024.

  • UBS O'Connor reported no remaining Xenon Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • UBS O'Connor sold 7,987 Xenon Pharmaceuticals shares in Q2 2024, an estimated $344K.
  • UBS O'Connor first reported a position in Xenon Pharmaceuticals in Q1 2022 and held it in 9 quarters.
  • UBS O'Connor's Xenon Pharmaceuticals position peaked at $2.93M in Q2 2022.
  • 213 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2024.

Based on UBS O'Connor's 13F filing for Q2 2024, filed 14 Aug 2024.